Lucid Diagnostics Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $184.0M
- Price
- $0.9643
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.41%
- Volume
- 415.4K
About
Lucid Diagnostics Inc. is a commercial-stage medical technology firm focused on diagnostic solutions. The company's primary objective is to serve patients afflicted with gastroesophageal reflux disease (GERD), commonly referred to as chronic heartburn or acid reflux, especially those at increased risk of developing precancerous esophageal conditions or the particularly aggressive esophageal adenocarcinoma. Their key product offerings include EsoGuard, an internally developed esophageal DNA test, and EsoCheck, a specialized device designed for collecting esophageal cells. Formed in 2018, Lucid Diagnostics Inc. has its headquarters in New York, New York, and operates as a subsidiary of PAVmed Inc.
Quick stats
Shares outstanding190.8M
Computed float156.5M
Float / shares82.0%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001799011
Websitehttps://www.luciddx.com
AI Summary
AI-generated1/21
standardbullishearnings
PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results
Lucid Diagnostics reported $1.5 million in Q2 revenue from its EsoGuard test, processing 2,770 tests, and secured its first laboratory benefit manager coverage policy recognizing the test as medically necessary.
Parent company PAVmed provided a corporate update noting progress across subsidiaries, including Veris Health's accelerated commercial rollout and PortIO's FDA pre-submission progress.
PAVmed reported Q2 operating expenses of $7.1 million and a GAAP net loss of $5.5 million, holding $3.8 million in cash as of June 30, 2026.
Red flags
- Parent company PAVmed cash balance of $3.8M is low relative to Q2 operating burn of $7.1M